Alkermes (ALKS) is pleased to announce the appointment of Joshua Reed as CFO, effective Monday, September 15. Reed will report to Richard Pops, CEO of Alkermes, and will join the company’s management committee. Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS: